Regeneron Pharmaceuticals Inc stock is traded at $959.41, with a volume of 1,215,378. It is up +4.73% in the last 24 hours and up +28.51% over the past month. Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
Previous Close:
$916.06
Open:
$904.99
24h Volume:
1,215,378
Relative Volume:
0.93
Market Cap:
$99.25B
Revenue:
$14.92B
Net Income/Loss:
$4.42B
P/E Ratio:
23.38
EPS:
$41.04
Net Cash Flow:
$3.79B
1W Performance:
+3.09%
1M Performance:
+28.51%
6M Performance:
+34.60%
1Y Performance:
+42.23%
1-Day Range:
$898.29$961.98
1-Week Range:
$887.04$961.98
52-Week Range:
$591.52$991.73
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
Name
Regeneron Pharmaceuticals IncSector
HealthcareIndustry
BiotechnologyPhone
(914) 847-7000Address
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS